Aspirin responsive platelet thrombophilia in essential thrombocythemia and polycythemia vera

Table 1 A Platelet kinetic, hemostatic and thromboxane B2 studies in normal individuals (control), asymptomatic essential thrombocythemia patients (E-), essential thrombocythemia patients suffering from erythromelalgia (E+) and the effect of acetylsalicylic acid (aspirin) in E+ patients

Study population	Control healthy	ET
		E-	E+	E+ treated
Aspirin treatment	No	No	No	Yes→E
Platelet kinetic study[22]
Patients (n)	6	10	10	7
Platelet survival (d)	8.0 ± 0.41	6.6 ± 0.31	4.2 ± 0.41	6.9 ± 0.4
Hemostatic studies[24]
Patients (n)	20	16	5	5
Platelet count (× 109/L)	256 ± 10	671 ± 66	689 ± 1051	857 ± 52
Platelet activation markers
Thrombomoduline (ng/mL)	40 ± 2.1	73 ± 41	90 ± 101	64 ± 12
PF4 (IU/108 plts)	1.6 ± 0.11	2.9 ± 0.51	9.1 ± 5.01	4.3 ± 3.3
β-TG (IU/108 plts)	16 ± 1.2	37 ± 6.6	128 ± 33	29 ± 15
Coagulation activation markers
F1+2 (nmol/L)	1.3 ± 0.1	1.2 ± 0.1	1.2 ± 0.4	1.1 ± 0.3
FDP (ng/mL)	669 ± 31	707 ± 51	702 ± 83	-

¹Significant difference. Data are expressed as mean ± SE. PF4: Platelet factor 4; β-TG: β-thromboglobulin; F1+2: Prothrombin fragment 1 + 2; FDP: Fibrin degradation products; ET: Essential thrombocythemia; E+: Erythromelalgia present; E-: Erythromelalgia absent. Originated from[22,24].